June 15, 2022 7:32am

The question, how will the words effect the cell and gene therapy sector?

Pre-open indications: 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 7:30 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are UP +0.47% (+144 points), S&P futures are UP +0.63% (+23 points) and NASDAQ futures are UP +0.83% (+94 points) early in the pre-open – so far,


Stock futures rose in early morning trading on Wednesday,

European stocks were higher,

Asia-Pacific stocks were mixed as Chinese indexes had gains.



The Dow closed DOWN -151.91 points (-0.50%); the S&P closed DOWN -14.15 points (-0.38%) while the Nasdaq closed UP +19.12 points (+0.18%)

The rate-setting Federal Open Market Committee will conclude its two-day meeting on Wednesday. The market is betting on a 94% chance of a 75-basis-point rate hike, the biggest increase since 1994, according to the CME Group’s FedWatch tool. (1 basis point equals 0.01%)

·         “The change in the headline from 50 basis points to 75 basis points reflects a stark reality but it also reflects the Fed’s determination to underscore its commitment to its mandate to maintain price stability,” said Quincy Krosby, chief equity strategist at LPL Financial. “It’s neither a trial balloon nor a lead balloon — it’s reality.” <CNBC>


RegMed Investors’ (RMi) closing bell: “volatility is truly an expletive, today. Be patient, lows will beget BUYs even as pessimism magnifies; not today, tomorrow or the next – it’s coming. However, net shorts are in vogue in a wait-and-see session on Tuesday” … https://www.regmedinvestors.com/articles/12473

Ebb and flow –

Q2/22 –

June – 4 positive and 6 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

…. For negative or positive indications – I will await the Fed decision ….


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed down -$0.40 to $4.50 with 100 shares traded after Monday’s +$ 0.15 with 100 shares traded, Friday’s +$0.065 with 295 shares traded, Thursday’s $0.00 with 43 shares traded and last Wednesday with 2 shares traded following last Tuesday’s $0.00 at $4.68 with 65 shares traded.

WARNING:  Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors. Another PPM -private placement – this one for $5.1 M without a price per share notification. Also, the terminal death lawsuit just got settled (4/28) for $6 M with a PPM – a preferred convertible debt financing.

Harvard BIOSCIENCE  (HBIO) and BSTG filed a new 8-K in lieu of cash payment < https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=116769338&type=HTML&formType=8-K&dateFiled=2022-06-13&cik=0001563665&CK=1563665&symbol=0001563665&companyName=Biostage >

BSTG seems to always finagling a finagle and NOTHING is CLEAN and STRAIGHTFORWARD.

 is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?

·         So, Has BSTG filed its Annual Report to the FDA, isn’t it a “Material Fact”?

·         Is yet ANOTHER financing on-going of 5+M shares being prepared to be sold?


The BOTTOM LINE: The cell and gene therapy suffered significant losses Thursday, Friday, Monday and Tuesday with the major indexes undercutting key short-term support. Surrounding the sector’s coverage group, decliners trounced winners.

That’s 6 of 10 June session being or closing negative …

I wonder and ... HOPE that or if algorithms will recognize their “rules>?

We are left with choosing to hang on to “our” portfolio position as it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Investors may want to at least consider taking partial profits – when they can; we are approaching earnings season, no sooner did we finish than we start again.

I STILL haven’t heard the bugle sound of a sustainable advance or rally … rising rates and slowing economic growth are not a supportive environment for investors.

Again, as have I written (repeatedly), “There's a battle in the cell and gene therapy sector between which or what breaks first: share pricing resistance or tumbling into yet another downturn as fear remains beneath the strength of any positive close” …

This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.

I have NOT seen ANY step-up of declining company investments by ANY CEOs and their management teams – WHY NOT?

I try to keep it simple … and short!

There is VALUE out there however, it’s about playing or betting the timing of the sector.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.